ALISO VIEJO, Calif., Jan. 13 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International today announced the appointment of Anders Lonner to its Board of Directors. Mr. Lonner was appointed to fill a vacant board position with a term that expires at the 2011 Annual Stockholders Meeting. Mr. Lonner's election brings the company's board to eight members.
Mr. Lonner has been Group President and Chief Executive Officer and a board member of Meda AB, a leading international specialty pharmaceutical company, since 1999. Prior to joining Meda AB, Mr. Lonner was Vice President, Nordic Region for Astra and then CEO of KaroBio. He also was the former Head of the Association for Pharmaceutical Companies in Sweden. Mr. Lonner has an M.B.A. from the University of Lund.
About Valeant
Valeant Pharmaceuticals International is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at http://www.valeant.com/.
(Logo: http://www.newscom.com/cgi-bin/prnh/20081125/VALEANTLOGO) Contact: Laurie W. Little Valeant Pharmaceuticals 949-461-6002
http://photoarchive.ap.org/
